Document:

Document

Exhibit 10.2

AMENDMENT TO EMPLOYMENT AGREEMENT
THIS AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) dated as of June 28, 2021, is by and between M.D.C. Holdings, Inc. (the “Company”) and David D. Mandarich (the “Executive”) and amends that Employment Agreement dated as of October 26, 2020, between the Company and the Executive (the “Agreement”).  All capitalized terms not otherwise defined in the Amendment have the meanings given them in the Agreement.
The Company and the Executive hereby amend the Agreement as follows:
1.    Section 3(c) of the Agreement is hereby amended to read in its entirety as follows:
(c)    Long-Term Incentive Compensation.  (i)  The Executive will continue to participate in the Company’s Equity Incentive Plan for employees, as it may be amended, and any successor or supplementary compensation and incentive plans or programs established by the Company (the “Equity Plans”).  Notwithstanding the foregoing, the Board of Directors may grant a special long-term incentive compensation award at any time.  Long-term incentive compensation awards are deemed “earned” if (1) the Executive is employed on the last day of the applicable performance period, or (2) the award is otherwise fully vested.  The payments the Executive is entitled to receive under the Equity Plans and this Section 3(c) are referred to herein as “Long-Term Incentive Compensation.”  
(ii) In the event of death, presumed death, the Executive becoming Totally Disabled as defined in Section 3(f)(i), termination of the Executive’s employment by the Company without Cause (which includes a non-renewal by the Company of this Agreement for each Additional Term) or termination by the employee for Good Reason as defined in Section 4(a)(iv), all outstanding unvested Awards (as defined in the Equity Plans) will be fully vested, exercisable, and/or payable at the maximum level (in other words, the Awards will be “Auto-Accelerated”) regardless of whether all vesting conditions relating to length of service, attainment of performance goals, or otherwise have been satisfied.  In the event of a Retirement as defined in Section 4(a)(v) or in the event of a Change in Control as defined in Section 4(a)(iii) following which the employment of the Executive is terminated by the Company,  (1) all outstanding unvested Awards (as defined in the Equity Plans) other than PSU awards shall be Auto-Accelerated, and (2) with respect to all unvested  PSU awards that are outstanding on a Termination Date (as defined below), the number of shares to be earned, issued and delivered to the Executive, if any, for such outstanding PSUs will be determined at the end of the performance periods in which such Retirement or termination of employment following a Change in Control occurs and will be issued and paid to the Executive as though he continued to be employed through the end of the performance period.
1

2.    Section 4(a)(vii)(2) of the Agreement is hereby amended to read in its entirety as follows:
(2)    Vesting of all unvested options, restricted stock and other equity awards and rights granted to the Executive under the Equity Incentive Plans will be as provided in Section 3(c).  In furtherance of the foregoing, in the event outstanding Stock Option Agreements or Restricted Stock Unit Agreements (but excluding all PSU agreements) does not provide accelerated vesting upon termination of employment the terms of such award shall be amended so that all existing options and restricted stock units (but excluding any PSUs) will fully vest as provided in Section 3(c).  Further, in the event that the fair market value of restricted stock units on the date of full vesting is less than the fair market value of the restricted stock units on the date of award, additional shares of stock will be granted on the date of full vesting so as to equalize the award value to equal the fair market value of the award on the date of grant.
3.    Section 5(e) of the Agreement is hereby amended to read in its entirety as follows:
(e)    This Section 5(e) shall be construed in accordance with Code Sections 280G and 4999, or any successor provisions thereto, and the guidance issued thereunder (collectively, “Section 280G”), and the terms “parachute payment” and “excess parachute payment” as used herein have the meanings ascribed to them under Section 280G.
(i)    If it shall be determined that the aggregate payments and benefits constituting parachute payments which, but for the operation of this provision, would become payable or distributable by the Company to or for the benefit of the Executive, pursuant to this Agreement, any other agreement, or any benefit plan (collectively, the “Total Payments”), would result in any excess parachute payments becoming subject to the excise tax imposed by Code Section 4999, or any successor provision thereto, or any interest or penalties with respect to such excise tax (such excise tax, together with such interest and penalties, collectively, the “Excise Tax”), then the Total Payments shall be reduced to an amount equal to one dollar less than the amount which would cause the parachute payments to be subject to the Excise Tax; provided that the reduction contemplated by this Section 5(e) shall be applied only if the net after-tax benefit to the Executive after such reduction would be greater than the net after-tax benefit to Executive without such reduction (notwithstanding the application of any Excise Tax on the unreduced Total Payments). For the avoidance of doubt, the Executive shall be responsible for the payment of any Excise Tax arising from the Total Payments.
(ii)    The Company will reduce or eliminate the Total Payments by first reducing or eliminating any cash parachute payments that 
2

do not constitute deferred compensation within the meaning of Section 409A, then by reducing or eliminating any other parachute payments that do not constitute deferred compensation within the meaning of Section 409A, then by reducing or eliminating all other parachute payments that do constitute deferred compensation within the meaning of Section 409A, beginning with those payments last to be paid, subject to and in accordance with all applicable requirements of Section 409A.
(iii)    Unless the Company and the Executive otherwise agree in writing, all calculations and determinations necessary to effectuate this provision, including without limitation determinations as to whether a reduction in payments or benefits is required and the amount thereof, whether any item of compensation constitutes a parachute payment, the amount, if any, subject to the Excise Tax (including determinations as to whether any portion of the excess parachute payments constitutes reasonable compensation for services actually rendered, within the meaning of Code Section 280G(b)(4)(B)), and the present value of any parachute payment, shall be made, consistent with Section 280G, by Ernst & Young LLP (the “Advisors”). For this purpose, the Advisors may make reasonable assumptions and approximations; may rely on reasonable, good faith interpretations concerning the application of Section 280G; and may rely upon such other tax, legal, valuation or other specialists as they deem appropriate. The Executive’s applicable federal, state, and local income taxes shall be computed at the highest applicable marginal rate, net of the maximum reduction, if any, in federal income taxes which could be obtained from a deduction of such state and local taxes. The Company and the Executive agree to furnish the Advisors with such information and documents as the Advisors reasonably request to make such calculations and determinations as soon as practicable upon such request. The Company shall direct the Advisors to provide the Executive with a written statement of its conclusions, setting forth the basis therefor, including detailed supporting calculations and copies of any written opinions or advice upon which such conclusions rely (the “Report”), within ten business days after their receipt of all required information and documents. The Executive shall have five business days thereafter to notify the Advisors and the Company in writing of any reasonable and substantive objections to the Report. The Company shall direct the Advisors to promptly consider in good faith and respond to such objections, and provide the Executive a revised Report reflecting appropriate adjustments (unless the Advisors determine that no adjustments are necessary). The Advisors’ final calculations and determinations (as adjusted, if applicable) shall be conclusive and binding on all parties for all purposes. The Company shall bear all costs the Advisors may reasonably incur in connection with the process contemplated by this Section 5(e).  
3

IN WITNESS WHEREOF, the Parties have duly executed this Amendment as of the date set forth above.
M.D.C. HOLDINGS, INC.

By:     /s/ Robert N. Martin                                          
Name:  Robert N. Martin 
    Title:    Senior Vice President and Chief Financial 
        Officer

EXECUTIVE

/s/ David D. Mandarich                                                      
David D. Mandarich
4EX-10.1

 Exhibit 10.1 

CONFIDENTIAL 
 CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS 
 EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE 

COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 

TEXT OMITTED FROM THIS EXHIBIT IS MARKED WITH [***] 
  

 
  

License and Supply Agreement 

CATALYST PHARMACEUTICALS, INC. 

- and - 
 DYDO PHARMA,
INC. 
 Dated as of: June 28, 2021 
  

 
  

 CONFIDENTIAL 
  

 LICENSE AND SUPPLY AGREEMENT 

THIS LICENSE and SUPPLY AGREEMENT (this “Agreement”) is made as of June 28, 2021 (the “Effective Date”)
by and between Catalyst Pharmaceuticals, Inc., 355 Alhambra Circle, Suite 801 Coral Gables, Florida, a corporation incorporated under the laws of the state of Delaware, United States of America (“CATALYST”), and DyDo
Pharma, Inc., 2-2-7 Nakanoshima, Kita-ku, Osaka, a corporation incorporated under the laws of Japan
(“DYDO”). 
 RECITALS 

WHEREAS, CATALYST markets and sells in the United States amifampridine 10 mg immediate release tablets (marketed as Firdapse®), and
holds certain intellectual property and other rights related to that Product; and 
 WHEREAS, DYDO has expertise in developing,
marketing and selling pharmaceutical products in Japan; and 
 WHEREAS, subject to and in accordance with the terms and conditions of
this Agreement, CATALYST and DYDO desire to have (a) CATALYST license to DYDO certain rights to develop and commercialize the Product in the Territory; (b) DYDO develop and commercialize the Product in the Territory; and (c) CATALYST
supply to DYDO the Product exclusively for sale in the Territory. 
 NOW, THEREFORE, in consideration of the mutual covenants
contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1. 
 DEFINITIONS

 1.1    Definitions. In addition to the terms defined elsewhere in this Agreement, the terms set forth
below (including correlative terms) shall be defined in this Agreement (including the recitals) as follows: 
  

	 	i.	 “Additional Formulation” means [***] 

 

	 	ii.	 “Affiliate” means, in respect of any party, a legal entity controlling, controlled by or under
common control with that party, with control meaning ownership of more than 50% of the capital or the voting power in such entity. 

  

	 	iii.	 “API” means the active pharmaceutical ingredient of the Product, namely amifampridine
phosphate. 

  

	 	iv.	 “API Supplier” means any third party who supplies the API used to manufacture the Product.

  

 CONFIDENTIAL 
  

	 	v.	 “Applicable Laws” means, with respect to any person, any domestic or foreign, federal, state
or local statute, treaty, law, ordinance, rule, regulation, administrative interpretation, order, writ, injunction, judicial decision, decree or other requirement of any governmental authority applicable to such person or any of such person’s
respective properties, assets, officers, directors, employees, consultants or agents (in connection with such officers’, directors’, employees’, consultants’ or agents’ activities on behalf of such person) as it relates to
this Agreement, including PMD Act. 

  

	 	vi.	 “Business Day” in relation to each Party means any day other than a Saturday, a Sunday, or any
statutory or public holiday on which banks are generally closed for regular business in the jurisdiction in which either Parties’ offices are located as specified in Section 18.1 hereof. 

 

	 	vii.	 “Calendar Year” means a twelve (12) -month period from January 1 of any year to
December 31 of the same year.  

  

	 	viii.	 “CATALYST License” means that certain License Agreement dated as of October 26, 2012
between BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), and CATALYST, as amended by Amendment No. 1 to License Agreement dated as of April 8, 2014, and Amendment No. 2 to License Agreement dated as of
May 29, 2019, and as assigned by BioMarin to SERB S.A (“SERB”) on January 21, 2020. 

  

	 	ix.	 “Combination Product” means a pharmaceutical product that contains both (a) the Product
and (b) one or more other active pharmaceutical ingredients (not including the API) or medical device which forms the basis for a separate product. 

  

	 	x.	 “Commercially Reasonable Efforts” means exercising such reasonable efforts and diligence
required in the exercise of “Diligent Efforts” under the CATALYST License to the extent such Diligent Efforts are analogous to such efforts in question under this Agreement. 

 

	 	xi.	 “Complaint” means complaint which direct or indirect customers of DYDO, including agents,
wholesalers, hospitals, medical institutes, doctors, physicians, medical practitioners, patients and patient groups, reasonably brought to DYDO of Defects or any other abnormality of the Products actually delivered to any of those.

  

	 	xii.	 “Compound” means amifampridine that is chemically known as
3,4-Diaminopyridine and includes any of its salt formulations that are metabolized in the human body into 3,4-Diaminopyridine. 

 

	 	xiii.	 “Contract Manufacturer” means contract manufacturers and suppliers engaged by CATALYST
relevant to the Product Marketed in the Territory and identified in Schedule A of this Agreement. 

  

	 	xiv.	 “Contract Manufacturing Agreement” means that certain [***]

  
 2 

 CONFIDENTIAL 
  

	 	
and all agreements between [***] and CATALYST related to the manufacturing of the Product including the Product Agreement dated [***] 

 

	 	xv.	 “Defective” means any Product which, when delivered to DYDO, fails to comply with (i) the
Specifications for manufacturing of the Product set forth in the Regulatory Approval, (ii) GMP or (iii) Applicable Laws. 

  

	 	xvi.	 “Development” means all activities relating to the development of the Product for use in the
Field in the Territory as required to: (i) establish the Product’s efficacy and safety profile; (ii) obtain and maintain Regulatory Approval; and (iii) obtain Orphan Drug Designation of the Product in the Territory. For the
avoidance of doubt, Development includes performing bridging studies, clinical trials, clinical studies and post-approval clinical studies, but does not include any Additional Formulation of the Product. 

 

	 	xvii.	 “DMF”, where applicable, means a drug master file governing the development and manufacture of
the API. 

  

	 	xviii.	 “Facility” means the manufacturing facilities of CATALYST or DYDO or any of their respective
Affiliates or subcontractors where the Product is manufactured. 

  

	 	xix.	 “FDA” means the U.S. Food and Drug Administration. 

 

	 	xx.	 “Field” means the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”) in humans.

  

	 	xxi.	 “GLP” means current Good Laboratory Practices as established under Applicable Law.

  

	 	xxii.	 “GMP” means current Good Manufacturing Practices for the manufacture of finished
pharmaceutical products in effect from time to time as established under Applicable Laws which set minimum standards to ensure that pharmaceutical products meet established requirements for identity, strength, quality and purity.

  

	 	xxiii.	 “Intellectual Property Rights” means any patent, trade secret, right in Know-How, right of confidence and any other intellectual or industrial property right of any nature whatsoever in any part of the world, whether registered or unregistered, but excludes any Trademark rights.

  

	 	xxiv.	 “IP Claim” means any claim, action or demand commenced or made against any Party by a Third
Party in relation to the Product that is based upon the contention that DYDO’s attempt to obtain a Regulatory Approval for the Product in the Territory, and/or the Marketing and Packaging of the Product in the Territory by DYDO infringes the
Intellectual Property Rights of any Third Party in the Territory. 

  

	 	xxv.	 “Know-How” means inventions, discoveries, trade
secrets, information, experience, data, formulas, procedures and results, including physical, chemical, biological, toxicological, pharmacological, clinical and veterinary data, dosage regimens, control assays and product specifications, but
excluding any Patents. 

  
 3 

 CONFIDENTIAL 
  

	 	xxvi.	 “Launch” means to release and become available for first commercial sale by DYDO under the
Marketing Authorization. 

  

	 	xxvii.	 “Launch Date” means the date of Launching.  

 

	 	xxviii.	 “Licensor” means the entity to whom CATALYST has obligations under the CATALYST License.

  

	 	xxix.	 “Losses” means any
out-of-pocket damages, liabilities, obligations, costs, expenses or losses, including reasonable legal fees and expenses, court costs, arbitration fees, penalties,
fines, and amounts paid in settlement of claims. 

  

	 	xxx.	 “Market” means, sell, offer to sell, promote, advertise, market, import and/or distribute.

  

	 	xxxi.	 “Marketing Authorization” means the marketing authorization approved by the MHLW
under Article 14 of PMD Act which is necessary to market the Products in the Territory. 

  

	 	xxxii.	 “MHLW” means the Minister of Health, Labor and Welfare of Japan, the Ministry of Health, Labor
and Welfare of Japan, or other department or agency which is delegated by the minister or ministry such as the Pharmaceuticals and Medical Devices Agency (“PMDA”) or any other governmental unit of the government of Japan or prefectural
government having authority over the regulation, development, approval, and sale, distribute, manufacture and packaging of drug products in the Territory from time to time under Applicable Laws including PMD Act. 

 

	 	xxxiii.	 “Net Sales” means: 

[***] 

  
 4 

 CONFIDENTIAL 
  

	 	xxxiv.	 “NHI Price” means the National Health Insurance price for the Product as set by the MHLW.

  

	 	xxxv.	 “Orphan Drug Designation” means the designation that the MHLW may grant if (1) the number
of patients who may use the drug are less than 50,000 in Japan, (2) the drug is indicated for the treatment of patients with serious diseases, including the
difficult-to-treat diseases and (3) there is no appropriate alternative drug or treatment, or higher efficacy or safety is expected compared with existing products.
Orphan Drug Designation provides an extension of the re-examination period up to 10 years. In case the MHLW or the government of Japan revise or replace such system for orphan drugs, the revised or similar
system shall apply. 

  

	 	xxxvi.	 “Packaging” means all material used to prepare fully packaged Product, including containers,
cartons, labelling, blister packs, inserts and shipping cases, as applicable. 

  
 5 

 CONFIDENTIAL 
  

	 	xxxvii.	 “Party” means any party to this Agreement referred to individually, and “Parties”
means the Parties to this Agreement referred to collectively. 

  

	 	xxxviii.	 “PMD Act” means the Act on Securing Quality, Efficacy and Safety of Products Including
Pharmaceuticals and Medical Devices (Act No. 145 of August 10, 1960, as amended) 

  

	 	xxxix.	 “Pharmacovigilance” means certain obligations or activities regarding the collection and
assessment of data pertaining to patient safety, and the monitoring and prevention of adverse events (including product complaints) associated with the Product and shall include all such obligations or activities required by Applicable Laws.

  

	 	xl.	 “Product” means the pharmaceutical product that is the subject of this Agreement, as described
in Schedule A of this Agreement, attached hereto and incorporated herein by reference. 

  

	 	xli.	 “Quality Agreement” means a Quality Assurance/Quality Control Agreement to be entered into by
the Parties which will set forth certain obligations of the Parties in relation to the manufacture, packaging, quality control and testing of the Product in accordance with GMP. 

 

	 	xlii.	 “Quarter” means the following three (3) month periods during a calendar year:
(i) from January 1 to March 31; (ii) from April 1 to June 30; (iii) from July 1 to September 30; and (iv) from October 1 to December 31. 

 

	 	xliii.	 “Regulatory Application” means an application for Regulatory Approval within the
Territory such as an application for Marketing Authorization granted by the MHLW pursuant to the PMD Act. 

  

	 	xliv.	 “Regulatory Approval” means the approval of a regulatory application by the applicable
regulatory authority and any other regulatory approvals required to sell a pharmaceutical product in the Territory. 

  

	 	xlv.	 “Regulatory Authority” means the applicable governmental regulatory health authorities in the
Territory responsible for regulating the manufacture, distribution, and sale of pharmaceutical products such as the MHLW. 

  

	 	xlvi.	 “Specifications” has the meaning set forth in Section 4.4(b). 

 

	 	xlvii.	 “Territory” means Japan and its territories, protectorates and possessions.

  

	 	xlviii.	 “Third Party” means any person or entity other than the Parties or Affiliates of either Party.

  

	 	xlix.	 “Trademarks” means any trademarks, trade names, trade-dress, logos, whether or not registered,
for the Product including (i) the registration of “Firdapse” in English characters under trademark no. 5344437 in Japan, (ii) the registration of “Firdapse” in Japanese characters under trademark no. 6246392 in Japan,
and (iii) any subsequently registered trademark for the Product. 

  
 6 

 CONFIDENTIAL 
  

	 	l.	 “Transfer Price” means the unit cost for the Product to be paid by DYDO to CATALYST for the
right to use the Regulatory Approval, licensed Know How and the right to import, market and sell the Product within the Territory, as per Schedule A of this Agreement. 

1.2    Interpretation of “Include”. Where the words “include”, “includes” or
“including” are used in this Agreement, they shall mean, respectively, “include without limitation”, “includes without limitation”, or “including without limitation”. 

ARTICLE 2. 
 LICENSE

 2.1    License. Subject to the terms and conditions of this Agreement, CATALYST hereby grants to DYDO
(a) an exclusive right and license under the Intellectual Property Rights and interest in the Trademarks controlled by or licensed to CATALYST (the “Licensed Technology”) to Market, and take other necessary steps to
commercialize and exploit the Product in the Field in the Territory, and (b) a co-exclusive with CATALYST and its Licensor right and license under the Licensed Technology to Develop and obtain Regulatory
Approval of the Product in Field in the Territory and to complete final packaging and labeling of the Product in accordance with Applicable Laws, in each case for sale in the Field in the Territory. For the avoidance of doubt, CATALYST hereby grants
to DYDO a co-exclusive with CATALYST and its Licensor right to use all necessary information controlled by or licensed to CATALYST including efficacy data, safety data,
de-identified patient data, manufacturing data, stability data, test reports, study reports, common technical documents and any other supporting documents related to
non-clinical studies, clinical studies, post-marketing studies, manufacturing, and any other activities for DYDO to Develop and Market the Product in the Territory. During the Term of this Agreement and so
long as DYDO is not in material breach of the Agreement, CATALYST will not grant to a Third Party any rights set forth herein on the Product or any Combination Product in the Field in the Territory without prior written consent of DYDO. 

2.2    Restrictions. DYDO shall not: 

(a)    Sublicense or subcontract the Licensed Technology to a Third Party without the prior written consent of CATALYST
which will not be unreasonably withheld by CATALYST; 
 (b)    use or register the Regulatory Approval or any
information or data contained therein, in any jurisdiction other than the Territory; 
 (c)    use the Regulatory
Approval or any information or data contained therein for any purpose except as contemplated under this Agreement; 

(d)    Market, directly or indirectly, the Product in any jurisdiction outside of the Territory and shall prohibit (and
strictly enforce such prohibition) its sublicensees, contractors and Affiliates from doing so; 

  
 7 

 CONFIDENTIAL 
  

 (e)    Manufacture the Product, except as specifically allowed herein; or

 (f)    Market, directly or indirectly, any Combination Product without the prior written consent of CATALYST. 

DYDO shall provide CATALYST, within fifteen (15) days of the effective date of any sublicenses, with the name of each sublicensee of its rights under
this Article 2 and a copy of the applicable sublicense agreement (provided that DYDO may redact portions of such sublicense agreement to the extent that such portions solely relate to any sublicensee’s proprietary information, technology, or
research, development or commercialization plans or as reasonably necessary to comply with any confidentiality provisions of such sublicense), and DYDO shall remain responsible and liable for each sublicensee’s compliance with the applicable
terms and conditions of this Agreement. 
 ARTICLE 3. 

PRODUCT DEVELOPMENT 

3.1    Overview. DYDO shall be solely responsible at its sole cost and expense for the Development of the Product
in the Territory. DYDO will exercise its Commercially Reasonable Efforts to perform the Development of the Product in a timely fashion, in a good scientific manner and in compliance with all Applicable Laws. Promptly after completion of the clinical
trials required as a part of Development of the Product, DYDO shall prepare and file a Regulatory Application with the Regulatory Authority to obtain Regulatory Approval of the Product. Subject to the other terms and conditions of this Agreement,
CATALYST shall exercise its Commercially Reasonable Efforts to support the Development and the Regulatory Application of the Product in the Territory by DYDO in order to assist DYDO in its efforts to obtain Regulatory Approval of the Product;
provided, that CATALYST shall not be obligated to incur any costs or expenses in so doing. Subject to the foregoing, such support will include: (i) responding to the reasonable inquiries of DYDO which are made by DYDO during the process of
completing the Regulatory Application regarding non-clinical studies, clinical studies and manufacturing of the Product, (ii) GCP inspection of either the clinical studies performed by CATALYST and its
Licensors (including BioMarin) or (if such sites remain available for such inspection) the sites at which such clinical studies were performed and (iii) analysis of clinical data if determined to be required by a Regulatory Authority. If
CATALYST elects to require the filing with the Regulatory Authorities in Japan of a DMF related to the Product and such filing is not requested or required by either DYDO or such Regulatory Authorities, then CATALYST will bear the cost of such
filing. 
 3.2    Development Plan. DYDO will prepare and provide to CATALYST a proposed plan to obtain and
maintain Regulatory Approval of the Product in the Territory within forty-five (45) days of the Effective Date. The Development Plan shall set forth a comprehensive program that is designed to generate the
non-clinical, clinical and regulatory information required for submitting the Regulatory Application and to obtain and maintain Regulatory Approval for the Product in the Territory. CATALYST may provide to
DYDO comments on such plan, DYDO will consider such comments in good faith and (subject to the other terms and conditions of this Agreement) DYDO will have final authority on whether or not to incorporate such comments into such plan. The completed
version of such plan is called the “Development Plan.” DYDO shall provide written updates to such Development Plan as part of development reports required by Section 3.4 and periodically as may be necessary to document in the
Development Plan any material changes to the plan to obtain Regulatory Approval, and shall provide copies of such updated Development Plan to CATALYST. 

  
 8 

 CONFIDENTIAL 
  

 3.3    Joint Development Committee. Within sixty (60) days of
the Effective Date, the Parties shall establish a joint development committee (the “JDC”). The JDC shall consist of four (4) members, two (2) of whom shall be designated by CATALYST and two (2) of whom shall be
designated by DYDO. Each Party shall have the right at any time and from time to time to designate a replacement, on a permanent or temporary basis, for any or all of its previously-designated members of the JDC, and to have non-members of the JDC who are employed by or contractors of such Party attend JDC meetings. The JDC shall review and discuss the proposed Development activities including the design of clinical trials and the
selection of clinical sites. Prior to the conduct of any clinical trials included in the Development activities, DYDO shall request a JDC meeting sufficiently in advance to allow meaningful review and discussion by the JDC of such Party’s
proposed clinical trial including the design thereof. The JDC shall hold meetings promptly following any request by a Party and at such other times (which, until Regulatory Approval has been obtained, is expected to be at least every six
(6) months) as its members may determine at a time and place mutually agreed upon by the Parties, including, as agreed, by telephone conference or video conference. Each Party’s representatives on the JDC shall give reasonable
consideration to the comments of the other Party’s representatives on the JDC, but the JDC will only have consultative powers and no decisions which may bind either Party shall be made by the JDC. 

3.4    Development Reports. Within fifteen (15) days after each full calendar year during which
DYDO is required to perform under the Development Plan, DYDO shall provide CATALYST with a written report that summarizes, in reasonable detail, all Development activities performed by DYDO and its Affiliates and Third Party contractors during such
year. DYDO shall also promptly (i) provide CATALYST with any additional information reasonably requested by CATALYST regarding Development of the Product by or on behalf of DYDO or its Affiliates, and (ii) notify CATALYST upon DYDO’s
initiation of any clinical trials or regulatory filings relating to Product. 
 3.5    Reserved Rights. Nothing
in this Agreement shall prevent CATALYST from conducting Development of the Product, or obtaining the regulatory approval and pursuing commercialization of the Product outside the Territory, including any ongoing and planned clinical studies. 

3.6    Maintenance. DYDO will undertake any and all clinical studies, phase IV clinical studies and any other
post-regulatory approval studies as may be required in accordance with the Regulatory Approval of the Product and otherwise take all such actions necessary to maintain such Regulatory Approval of the Product in effect. 

3.7    Additional Product Development. 

[***] 

  
 9 

 CONFIDENTIAL 
  

 ARTICLE 4. 

REGULATORY APPROVAL 

4.1    Regulatory Application and Other Filings. DYDO shall be solely responsible at its sole cost and expense
(subject to the other terms and conditions of this Agreement) for all regulatory filings (including the Regulatory Application) with respect to the Product in the Territory. DYDO shall, prior to making any such regulatory filing (including the
Regulatory Application), provide CATALYST with a substantially final draft of such proposed regulatory filing. DYDO shall consider in good faith any comments provided to DYDO by CATALYST with respect to such proposed filing, and (subject to the
other terms and conditions of this Agreement) DYDO will have final authority over the contents of any such proposed filing. Notwithstanding the foregoing, the specifications of the Product included in the dossier for the first filing of the
Regulatory Application will be the specifications for the Product sold in the United States and approved by the FDA. DYDO will promptly provide to CATALYST copies of all material written or electronic communications received by it from, or sent by
it to any Regulatory Authority in the 

  
 10 

 CONFIDENTIAL 
  

 
Territory with respect to obtaining and maintaining Regulatory Approval for the Product and copies of all material contacts reports produced by DYDO (all such material written or electronic
communications and contact reports, collectively, the “Communications”). Such Communications may be provided by DYDO to CATALYST in Japanese, provided that DYDO promptly provides to CATALYST a summary, prepared in English, of all of
the material contents of such Communications (which, with respect to the Regulatory Application, need only identify such Communications as such). Subject to the permission of the applicable Regulatory Authority, DYDO will allow representatives of
CATALYST to attend meetings with Regulatory Authorities in the Territory which are related to the Product. 

4.2    Regulatory Data. DYDO will provide CATALYST on a timely basis with copies of all material pre-clinical and clinical data generated or compiled in connection with the development or commercialization of the Product via electronic copies of such data in a form that may be analyzed and manipulated by
CATALYST. For clarity, this shall include all analytical data obtained with respect to the Product, case report forms, patient exposure data, pregnancy registry data, if applicable, and patient medical records generated during clinical trials, and
any data generated during post-marketing studies or during commercialization. Further, it shall include all other clinical trial and available post-approval patient safety and registry study data, including historical regulatory data contained in
patient registry filings and files. Such data will be considered to be timely provided if it is provided promptly (within thirty (30) calendar days) following request. 

4.3    Pharmacovigilance Agreement. Subject to the terms and conditions of this Agreement, and within three
(3) months after the Effective Date, CATALYST and DYDO shall finalize the responsibilities of the Parties to protect patients and promote their well-being in a written agreement (the “Pharmacovigilance Agreement”) to be entered
into by the Parties that will include a safety data exchange agreement and the obligations of the Parties to fulfill their respective reporting responsibilities. Such obligations of CATALYST shall include informing DYDO about safety data of the
Product sold outside of the Territory including the European Union. Legal responsibility in respect of pharmacovigilance and other regulatory requirements as between the Parties shall reside with the respective holder of the Regulatory Approval in
the respective jurisdictions meaning for CATALYST, the US, and for DYDO, the Territory. In the event of a conflict between the Pharmacovigilance Agreement and this Agreement with respect to any safety-related matters, including compliance with all
regulatory obligations, the provisions of the Pharmacovigilance Agreement shall prevail. In the event of a conflict between the Pharmacovigilance Agreement and this Agreement with respect to any commercial matters, including allocation of risk,
liability and financial responsibility, the provisions of this Agreement shall prevail. 
 4.4    Specifications.
 
 (a)     DYDO will exercise Commercially Reasonable Efforts to obtain Regulatory Approval for the Product and
exercise Commercially Reasonable Efforts to cause such Regulatory Approval to incorporate the specifications for the Product which are the same as those specifications which have been approved by the FDA. 

  
 11 

 CONFIDENTIAL 
  

 (b)    In the event the Regulatory Authority requires changes to those
specifications which have been approved by the FDA, DYDO will immediately inform CATALYST and the Parties will exercise commercially reasonable efforts to achieve agreement on the feasibility of those changes to the specifications. Subject to either
the Regulatory Authority approving the specifications for the Product sold in the United States and approved by the FDA or achieving such agreement of the Parties on the changed specifications, the specifications which are approved by the Regulatory
Authority will be the specifications for the Product in the Territory (the “Specifications”). The Specifications may not be changed without first obtaining the mutual written approval of the Parties. 

(c)    If the Parties are unable to agree on changes to the specifications, then either Party may terminate the Agreement
by providing a written notice to the other Party. As a result of this termination, DYDO shall become exempted in any case from the Milestone Payment due on Regulatory Approval (JPY [***]) to CATALYST, and CATALYST shall become prohibited from,
directly or indirectly, Marketing the Product in the Territory except as set forth in Section 4.4(d). 
 (d)    If
this Agreement is terminated under Section 4.4(c), then [***] 
 ARTICLE 5. 

EXCLUSIVITY AND COMMERCIALIZATION 

5.1    Commercialization Obligation. DYDO will exercise Commercially Reasonable Efforts to Market the
Product to customers in the Territory during the Term at its sole cost and expense in accordance with the terms of this Agreement and Applicable Laws. Such efforts shall include the Launch of the Product, the preparation and delivery to CATALYST of:
(i) an annual marketing plan for the Product (the first of which shall be delivered prior to the Launch Date); and (ii) sales projections for the Product on an annual basis. DYDO will provide CATALYST an opportunity to comment on such
annual marketing plans, and will consider CATALYST’s comments in good faith, but the final marketing plan shall be determined by DYDO subject to complying with the other terms and conditions of this Agreement. 

  
 12 

 CONFIDENTIAL 
  

 5.2    Exclusive Supplier;
Non-Competition. During the Term of this Agreement, (i) DYDO shall purchase all of its requirements for the Product from and shall source and purchase the Product for sale in the Territory exclusively
from CATALYST, and (ii) DYDO shall not directly or indirectly Develop or Market any other potassium channel blocker or any competitive product developed or commercialized for use in the Field in the Territory or support any such activities.
During the Term of this Agreement, except as provided in this Agreement with respect to an AI Product or an AF Product, CATALYST shall not directly or indirectly Market in the Territory any potassium channel blocker or any competitive product
developed or commercialized for use in the Field in the Territory or support any such activities. 

5.3    Reports. After the Launch of the Product, DYDO shall within sixty (60) days after the completion of
each calendar year during the Term, provide to CATALYST, a report describing the selling resources deployment, including budget and spend on marketing of the Product for such year, as well as a report summarizing the status of reimbursement
approvals and pricing approvals and filings in terms of formulary listings and reimbursement pricing tiers for the Product in the Territory. 

(a)    DYDO shall provide to CATALYST such information and promotional, marketing and advertising materials with respect
to its Market activities regarding the Product as CATALYST shall reasonably request from time to time, including providing to CATALYST a pre-Launch marketing plan prior to initially filing the Regulatory
Application. CATALYST shall provide DYDO, initially within six (6) months of Effective Date, and thereafter upon DYDO’s reasonable request without delay, with such information and specimen copies of CATALYST’s currently used
promotional, marketing and advertising materials with respect to its Market activities for the Product in the United States to the extent that such promotional, marketing and advertising materials may support DYDO to Market and make Marketing and pre-Marketing plans for the Product in the Territory. DYDO shall not be required to provide CATALYST with such information and promotional, marketing and advertising materials with more granularity than those
provided by CATALYST. 
 (b)    For the avoidance of doubt, DYDO, at its own cost and expense, shall be responsible for
training of all sales representatives who are, or will be, Marketing the Products in the Territory, development of websites, advertising, and supporting materials (including, without limitation, print advertising, brochures, leaflet and similar
materials). 
 5.4    Trademarks. 

(a)    DYDO hereby acknowledges that CATALYST has been granted an exclusive and royalty free license to use the Trademarks
in the Territory, and that CATALYST is sublicensing the Trademarks to DYDO for use in the Territory in connection with the Product during the Term of this Agreement. DYDO shall not, during the Term or thereafter, register, use, or attempt to obtain
any right in and to any Trademarks or in and to any name, logo or trademark confusingly similar thereto, including, without limitation, by adding to or supplementing the Trademarks with additional words or phrases. CATALYST shall have the right to
exercise quality control over DYDO’s use of the Trademarks to a degree reasonably necessary to maintain the validity of the Trademarks, as applicable, and to protect the goodwill associated therewith. CATALYST shall be solely responsible for
the filing, prosecution and maintenance of the Trademarks in Japan, and all costs and expenses related thereto. 

  
 13 

 CONFIDENTIAL 
  

 (b)    In the event that a Regulatory Authority indicates that the use of
the brand name Firdapse or its phonetic spelling in Japanese language is unacceptable in Japan, [***] 
 ARTICLE 6. 

MANUFACTURE OF PRODUCT 

6.1    Supply Responsibility. Subject to the terms and conditions of this Agreement, CATALYST will be responsible
for manufacturing and supply Product necessary for the clinical and commercial use in the Territory. 

6.2    Manufacturing Accreditation. DYDO, having CATALYST as an intermediary between DYDO and Contract
Manufacturers, will be responsible for the accreditation process of all manufacturing sites, as per regulatory requirements and to the extent required by DYDO or Applicable Laws. The Parties will equally share up to US$[***] (US$[***] for each
Party) of Third Party expenses related to activities required by DYDO and related to any required accreditation of the US supply chain to provide DYDO with Product for sale in Japan. DYDO will be solely responsible for any such expenses which it
incurs over US$[***]. CATALYST will be solely responsible for any Third Party expenses arising from activities requested by CATALYST relating to the accreditation of the US supply chain to provide DYDO with Product for sale in Japan to the extent
(if any) such activities are outside or beyond the scope of activities which are either requested by DYDO or any Regulatory Authority or within the scope of DYDO’s responsibilities. 

6.3    Restrictions on Changes to Product. The Parties acknowledge that, once the Regulatory Approval has been
obtained, any change whatsoever to the Product or any related process, method or procedure may impact the regulatory status of the Product in the Territory. Without limitation to any other provision of this Agreement, neither CATALYST nor its
Contract Manufacturer will make any changes whatsoever to the Product without first informing DYDO and, to the extent any such changes result in any change in the Specifications which would require Regulatory Approval, obtaining DYDO’s
agreement to such changes. DYDO will obtain all necessary approvals from the applicable Regulatory Authorities for any such changes agreed upon by DYDO. DYDO will use Commercially Reasonable Efforts to submit any changes without delay and shall pay
all fees and charges payable to the applicable Regulatory Authorities which may be required to update the Regulatory Approval in connection with any change to the Product. 

  
 14 

 CONFIDENTIAL 
  

 6.4    Packaging. CATALYST shall supply the Product to DYDO
in [***] count labeled bottles for both clinical and commercial purposes. Product supplied for clinical trial purposes shall be in the form of US approved, commercially available Product manufactured for sale in the US market and will be provided to
DYDO for use research purposes only and may be provided under labeling used for such bottles in the United States. For Product supply for commercial purposes, DYDO will provide at its expense the final template for the label and artwork for the
Product approved for use in Japan and suitable for use on the bottle in which CATALYST supplies such Product. A sample bottle on which the label and artwork would be affixed shall be provided to DYDO at a reasonable time prior to filing the initial
Regulatory Application. CATALYST shall provide DYDO with a sample bottle with a sample of the printed label and artwork attached for final approval by DYDO of such label and artwork. 

6.5    Manufacturing Facility. All Product supplied to DYDO pursuant to this Agreement shall be manufactured only
by CATALYST’s designated Facility described in Schedule A, or at such other Affiliate or subcontractor as may be mutually agreed between the Parties in writing, such agreement not to be reasonably withheld, and which complies with the
requirements of this Section 6. 
 6.6    Inspections. If DYDO or CATALYST (as applicable, the
“Recipient”) receives any notification of any inspection of the Facility by any regulatory authority, relating directly or indirectly to the Product in the Territory, then the Recipient shall (i) notify the other Party of the
notice of the inspection within three (3) Business Day. If DYDO or CATALYST is in receipt of any Form FDA-483 or any warning letter or similar correspondence from any Regulatory Authority that is directly
or indirectly related to the Product, then the Recipient shall (ii) notify the other Party within five (5) Business Days and will provide a copy (redacted as necessary) of such report/letter/communication. The Recipient (iii) will
furnish the other Party with copies (redacted as necessary) of reports, notices or other communications received as a result of any such inspection; (iv) provide to the other Party a written plan for correcting such deficiencies documented by
the Regulatory Authorities, including a proposed timetable for implementing such corrections; (v) ensure that any of the foregoing deficiencies are corrected as soon as reasonably possible; and (vi) exercise its Commercially Reasonable
Efforts in order not to disrupt supply of the Product in the Territory. Notwithstanding the foregoing, the Parties shall not be held responsible for any non-compliance with the foregoing clauses
(i) through (vi) of this section to the extent such Party’s contract manufacturers or vendors do not so comply; provided, that each Party shall cooperate in good faith with the other Party and exercise its commercially reasonable efforts
to enforce such compliance by its contract manufacturers and vendors to the extent that it is contractually entitled to do so. 

6.7    Quality Assurance/Quality Control. The Parties shall enter into a separate Quality Agreement before the
earlier of: (i) the first commercial supply of any Product by CATALYST to DYDO; and (ii) six (6) months from the signing of this Agreement. The terms of the Quality Agreement shall among other things (a) include both Parties’
obligation to notify the other of deviations from Specifications, (b) address how to handle Complaints between the Parties and (c) apply to all Product manufactured and supplied by CATALYST pursuant to this Agreement. In the event of a
conflict between the Quality Agreement and this Agreement with respect to quality-related matters, including compliance with GMP and all other quality obligations, the provisions of the Quality Agreement shall prevail. In the event of a conflict
between the Quality Agreement and this Agreement with respect to any commercial matters, including allocation of risk, liability, and financial responsibility, then the provisions of this Agreement shall prevail. 

  
 15 

 CONFIDENTIAL 
  

 ARTICLE 7. 

MILESTONE AND OTHER PAYMENTS; REPORTING OF NET SALES 

7.1    Milestones and Other Payments. DYDO shall make the following payments to CATALYST upon the occurrence or
achievement of the respective associated event (each a “Milestone Payment”), as follows: 
  

			
	 Event
	  	 Payment

		
	Effective Date	  	JPY [***] (the “Up-Front Payment”)
		
	Upon acceptance of filing of the Regulatory Application for the Product by the Regulatory Authority (the “Filing Milestone”)	  	JPY [***]
		
	Upon the first Regulatory Approval of the Product	  	JPY [***]
		
	Upon the first time that Net Sales of the Product in any consecutive 12-month period exceed JPY [***]	  	JPY [***]
		
	Upon the first time that Net Sales of the Product in any consecutive 12-month period exceed JPY [***]	  	JPY [***]

 All Milestone Payments shall be non-cancellable and
non-refundable and shall be made by bank or wire transfer of funds available for immediate credit. Except for the Up-Front Payment (which shall be made on or before
thirty (30) Business Days after the Effective Date), all of the foregoing payments shall be made within twenty (20) Business Days following the occurrence of the associated event triggering such payment obligation. 

7.2    Quarterly Reports. 

(a)    DYDO shall provide to CATALYST preliminary written reports not more than four (4) Business Days after the end
of each Calendar Quarter and follow-on written reports (reconciling the preliminary reports, as necessary) not more than nine (9) Business Days after the end of each Calendar Quarter covering all sales of
the Product for which invoices were sent during such Calendar Quarter in the Territory by DYDO, its Affiliates, or Sublicensees. 

(b)    Each report required under Section 7.2(a) shall certify for the period in question: 

(i)    gross sales of Product in the Territory during the applicable Calendar Quarter; 

(ii)    calculation of Net Sales for the applicable Quarter, along with cumulative Net Sales for the then-current
Calendar Year, reported in both JPY and US Dollars in accordance with the exchange rate specified in Section 18.13; and 

  
 16 

 CONFIDENTIAL 
  

 (iii)    such other information as CATALYST may reasonably request to
facilitate the performance by CATALYST of its obligation to timely report “Net Sales” under the CATALYST License and pay the applicable royalty with respect thereto. 

Such reports shall be certified by DYDO to CATALYST as accurate and complete in accordance with the terms of this Agreement. 

(c)    The information contained in each report under this Section 7.2 shall be considered Confidential Information
of CATALYST and DYDO. DYDO and CATALYST shall cooperate with one another to facilitate the performance by CATALYST of its obligations under the CATALYST License described in Section 7.2(b)(iii). 

7.3    Accounting. DYDO agrees to keep full, clear and accurate records for a period of at least seven
(7) years after the relevant Net Sales report pursuant to this Agreement, setting forth the sales and other disposition of Products sold or otherwise disposed of in sufficient detail to enable the Milestone Payments and royalties and
compensation payable by CATALYST to Licensor to be determined. DYDO further agrees to permit its books and records to be examined by an independent accounting firm selected by CATALYST or Licensor reasonably acceptable to DYDO (subject to written
obligations of confidentiality to DYDO that are no less stringent than the obligation of confidentiality described in Article 17), at reasonable times and upon reasonable notice, to examine only those records as may be necessary to verify reports
provided pursuant to Section 7.2. Such audit shall not be performed more frequently than once per Calendar Year for any Calendar Year ending not more than three (3) years prior to such year, nor more frequently than once for each of
CATALYST and Licensor with respect to records covering any specific period of time. Such examination is to be made at CATALYST’s or Licensor’s (as applicable) expense, except in the event that the results of the audit reveal an
underpayment of royalties payable to Licensor under the CATALYST License or Milestone Payments to CATALYST under this Agreement exceeding five percent (5%) over the period being audited or a delay in payment of any Milestone Payments (which shall
refer to the case where, because Net Sales have not been correctly reported, a Milestone Payment dependent on reaching a certain level of Net Sales has not been paid when it should have been paid), in which case reasonable audit fees for such
examination shall be paid by DYDO. 
 ARTICLE 8. 

PRODUCT SUPPLY 

8.1    Forecasts and Purchase Orders. 

[***] 

  
 17 

 CONFIDENTIAL 
  

 8.2    Batch Size and Minimum Order Quantity. [***] 

8.3    Price and Payment. 

(1)    Method of Payment. All payments made by DYDO to CATALYST pursuant to this Agreement shall be
made within thirty (30) days of DYDO’s receipt of the invoice by bank or wire transfer or as CATALYST may otherwise direct. Payment shall not constitute approval or disapproval of any Product shipment. 

(2)    Delays in Payment. If DYDO fails to pay the invoice issued for any shipment of the Product or
any other amount due from it to CATALYST on a timely basis, interest at the rate of [***] percent ([***]%) on the unpaid amount per month of delay shall be due from DYDO to CATALYST. 

(3)    Product Purchase Pricing. CATALYST shall supply the Product to DYDO for both clinical use and
commercial sale at the Transfer Price as stated in Schedule A. The Transfer Price is inclusive of all royalties and trademark fees. 

  
 18 

 CONFIDENTIAL 
  

 8.4    Taxes. DYDO shall deduct or withhold from payments to
CATALYST only those taxes that are required by Applicable Laws to be so withheld, each Party will cooperate with the other Party to obtain the benefit of the tax treaty applicable between the US and Japan prior to any payment being made by DYDO
under this Agreement and each Party shall use commercially reasonable efforts to minimize the tax withholding obligations hereunder. DYDO shall submit to CATALYST appropriate proof of payment of tax withholdings as well as official receipts within a
reasonable period of time not to exceed sixty (60) days after the end of each Quarter. 
 8.5    Delivery.
Delivery of each order of the Product shall be made [***] 
 8.6    Vision System Inspection. If DYDO requires
computerized vision system inspection of the bulk tablets prior to packaging, any additional costs attributed to enabling or performing the inspection will be paid by DYDO. For the avoidance of doubt, any change in the Specifications or the
protocols for release of the Product by CATALYST’s Contract Manufacturer requires the prior written approval of both Parties. 

8.7    Testing. CATALYST or its Contract Manufacturers shall test all Product prior to delivery to DYDO to ensure
that the Product meets the Specifications. Upon the delivery of each shipment of Product, CATALYST or its Contract Manufacturers shall provide to DYDO a certificate of analysis which verifies that the Product complies with the Specifications. DYDO
will perform the final quality control testing based on the Regulatory Approval and then release all quantities of the Product for both clinical and commercial purposes. 

8.8    Defective Product. 

(1)    Notification. If any shipment of Product is Defective in relation to any matter discoverable
upon visual inspection made by DYDO with reasonable care, then DYDO will notify CATALYST as soon as practicable (to allow time for DYDO and CATALYST to collaborate about the issue before notifications are required to be issued to Contract
Manufacturers) and in any event within twenty-seven (27) days of receipt of the Product. DYDO shall be deemed to have accepted the Products within twenty-seven (27) days of receipt of the Products, except to the extent that DYDO has
notified CATALYST as set forth herein. If any shipment of Product is Defective in relation to any matter which is not discoverable upon visual inspection made by DYDO with reasonable care, then DYDO will immediately notify CATALYST upon discovery.
CATALYST will initiate an investigation with Patheon and will notify DYDO of the outcome of the investigation, and as to whether it confirms or disputes that the Product is Defective.  

  
 19 

 CONFIDENTIAL 
  

 (2)    Review; Independent Testing Laboratory. If
CATALYST does not agree with a claim by DYDO that any Product is Defective, then the Parties shall submit information regarding the disputed shipment to each other for review. If the Parties cannot agree as to whether the Product is Defective, then
upon the request of either Party the dispute shall be submitted to a mutually acceptable independent laboratory with a minimum of ten (10) years of experience in testing pharmaceutical products and complying with guidelines and regulations in
the United States. The independent laboratory shall act as an expert whose determination shall be final and binding upon the Parties, except in the case of manifest error. If the independent laboratory determines that the Product is not Defective,
then DYDO shall pay for the Product (if it has not already done so) within thirty (30) days of receiving notice of the independent laboratory’s decision. The costs of the independent laboratory shall be borne by the Party with whom the
independent laboratory disagrees. 
 (3)    Remedy for Defective Product. If any Product delivered
by CATALYST to DYDO is finally agreed or determined to be Defective by CATALYST or by an independent laboratory as described in 8.8(2), then CATALYST shall, at DYDO’s discretion, and without limitation to CATALYST’s indemnification
obligations, either replace the Defective Product at no additional cost to DYDO or (to the extent that DYDO has already paid for the Defective Product) give credit to DYDO for the Defective units and all costs paid by DYDO in relation thereto
(including freight, insurance and all applicable taxes). DYDO will, at CATALYST’s expense and in accordance with CATALYST’s written instructions, either return or destroy all Defective Product. All claims made concerning Defective Products
must be made pursuant to Article 8.8(1). In the case where DYDO shall fail to notify in accordance with Article 8.8(1), DYDO shall be deemed to have waived any remedies with respect to Defective Products. 

ARTICLE 9. 
 RECORDS

 9.1    Records. CATALYST or its Contract Manufacturer shall maintain all records necessary to comply with
all Applicable Laws relating to the testing, manufacture, packaging, storage and supply of the Product, and the performance of its obligations under this Agreement and all relevant Contract Manufacturing Agreements. All such records shall be
maintained for such period as may be required per GMP and pursuant to Applicable Laws; provided, however, that all records relating to the manufacture, stability and quality control (including deviations) of each batch of the Product shall be
retained at minimum until the first anniversary of the end of the approved shelf life for all Product from such batch. 

9.2    Samples and Batch Records. CATALYST or Contract Manufacturer shall prepare and maintain batch records and
file samples, properly stored, for each lot or batch of Product manufactured and shipped hereunder in compliance with all GMPs and other Applicable Laws pertaining thereto. DYDO will retain samples properly stored in the Territory in conformity with
GMP and Regulatory Authority requirements. 

  
 20 

 CONFIDENTIAL 
  

 9.3    Ongoing Stability. CATALYST or its Contract Manufacturer,
at their own cost, shall conduct ongoing stability studies for the Product according to the Specifications and the Contract Manufacturing Agreement. Any additional stability studies requested by DYDO shall be performed at the expense of DYDO. 

ARTICLE 10. 
 PRODUCT
RECALL 
 10.1    Product Recall. 

(1)    If any Regulatory Authority issues or requests a recall or takes similar action in connection with
the Product in the Territory, or if either Party reasonably determines after consultation with the other Party that an event has occurred which may result in the need for a recall or market withdrawal of, or other corrective action regarding, the
Product, then the Party notified of or wishing to implement such recall or other action shall inform the other Party thereof. The Parties shall promptly discuss and work together to effect an appropriate course of action to implement any recall or
other corrective actions, provided that neither Party shall be prohibited from unilaterally taking any action, including recall of the Products, which it determines in good faith it is required to take to minimize risk to public health and safety or
to comply with Applicable Laws. DYDO shall be responsible for notifying the applicable Regulatory Authority of any recall or other corrective action related to the Product in the Territory. 

(2)    Without limitation to the Parties’ respective indemnification obligations under this Agreement
regarding third party claims, if a Party (the “Innocent Party”) is reasonably required to incur any out-of-pocket expenses due to a Product
recall in the Territory (“Recall Expenses”), and if the reason for the recall or other corrective action in the Territory is a matter for which the other Party (the “Responsible Party”) is obligated to indemnify the
Innocent Party as provided in Article 16 of this Agreement, then the Responsible Party shall be liable for all Recall Expenses of both Parties. Without limitation, the Recall Expenses for which the Responsible Party shall be liable include
notification expenses, costs for the return of recalled Product, costs to destroy recalled Product, and customer fees and penalties arising due to the recall. The Innocent Party shall provide to the Responsible Party documentation which verifies all
Recall Expenses for which liability or reimbursement is claimed. 
 (3)     If a recall is not due to the
fault or responsibility of either Party, then the Parties shall share the Recall Expenses equally. 

(4)    The Parties will cooperate and assist each other on all recalls or other corrective action. If
possible, the Parties shall discuss and agree on Recall Expenses prior to being incurred, provided that neither Party shall be prohibited from unilaterally taking any action or incurring any reasonable Recall Expenses which it determines in good
faith it is required to take or incur to minimize risk to public health and safety or to comply with Applicable Laws. 

  
 21 

 CONFIDENTIAL 
  

 ARTICLE 11. 

INTELLECTUAL PROPERTY RIGHTS 

11.1    Reservation of Rights. Except for the licenses granted to DYDO under this Agreement, no right, title, or
interest is granted, whether expressly or by implication, to any technology or Intellectual Property Rights owned by either Party. Each Party hereby reserves all rights not expressly granted under this Agreement. 

11.2    Trademarks. Subject to Section 5.4, CATALYST shall be responsible for the selection, registration and
maintenance of all Trademarks used by DYDO in connection with the Product in the Territory, at CATALYST’s cost. DYDO shall not acquire or assert any right, title, and interest in and to the Trademarks or marks substantially similar to the
Trademarks. DYDO shall not use any Trademark in connection with the Marketing of the Product other than as contemplated herein. 

11.3    IP Claims. 

(1)    Intellectual Property Representation. CATALYST represents and warrants that, to the best of
its knowledge without investigation, the manufacture of the Product by or on behalf of CATALYST (including the route of synthesis, formulation and manufacturing process) for supply to DYDO and the distribution and sale of the Product by DYDO in the
Territory in accordance with the provisions of this Agreement does not infringe upon the Intellectual Property Rights of any Third Party in the United States or the Territory. CATALYST also represents and warrants that it does not own or license any
granted or pending patent applications in the Territory with respect to the Product, including any patents/applications relating to the use or manufacturing of the Product. 

(2)    Defense of IP Claims. During the Term of this Agreement, each Party shall bring to the
attention of the other Party all information regarding potential infringement of Third Party Intellectual Property Rights by the development, manufacture, production, use, importation, offer for sale, or sale of the Product in the Territory. Upon
the request of either Party, the Parties shall agree on and enter into a “common interest agreement” wherein such Parties agree to their shared, mutual interest in the outcome of such potential dispute. If CATALYST and/or DYDO are named as
defendant(s) in any IP Claim filed by a Third Party concerning the development, manufacture, production, use, importation, offer for sale, or sale of the Product in the Territory, then CATALYST shall lead and control the defense of such IP Claim;
provided, that, any settlement of such IP Claim shall require the consent of DYDO which shall not be unreasonably withheld. CATALYST and DYDO shall each bear half of all Losses in connection with such IP Claims. 

(3)    Termination Due to IP Claim. If an IP Claim is threatened or commenced against any Party, and
if the Parties reasonably determine that the likelihood and consequences of an unfavorable ruling warrants that DYDO refrain from Marketing the Product in the Territory, or if DYDO agrees to refrain from Marketing the Product in the Territory
pursuant to a settlement of an IP Claim, or if a court of competent jurisdiction makes a final determination that the Marketing of the Product in the Territory infringes the 

  
 22 

 CONFIDENTIAL 
  

 
Intellectual Property Rights in the Territory of a Third Party and all rights to appeal have been exhausted or expired, then either DYDO or CATALYST may terminate this Agreement upon delivering
written notice to the other Party. In no event will Milestone Payments under Article 7.1 which have already been paid by DYDO to CATALYST be reimbursed by CATALYST to DYDO. 

11.4    Patent Enforcement. 

(a)    Notice. If either Party becomes aware of any infringement, threatened infringement, or alleged infringement
of a licensed patent or other exclusivity rights in the Territory (an “Infringement”), it will promptly notify the other Party thereof including available evidence of Infringement. 

(b)    Enforcement in the Territory. DYDO will have the first right (but not the obligation), at its sole expense,
to take the appropriate steps to address any Infringement by enforcing such rights, including without limitation the initiation of a suit, proceeding or other legal action by counsel of its own choice. CATALYST will have the right, at its own
expense, to participate in (but not control) such suit, proceeding or action by counsel of its own choice. If DYDO fails to take the appropriate steps to address a particular Infringement within ninety (90) days after the date one Party has
provided notice to the other Party of such Infringement, then CATALYST or Licensor will have the right (but not the obligation), at its sole expense, to take the appropriate steps to address such Infringement including the initiation of a suit,
proceeding or other legal action by counsel of its own choice. DYDO will have the right, at its own expense, to participate in (but not control) such suit, proceeding or action by counsel of its own choice. 

(c)    Enforcement Outside the Territory. CATALYST or Licensor will have the sole right (but not the obligation),
at is sole discretion and expense, to take the appropriate steps to address any infringement of rights to exclusivity outside of the Territory. 

(d)    Cooperation. If one Party brings any suit, action or proceeding under this Section 11.4, the other
Party agrees to be joined as party plaintiff, at such enforcing Party’s request and expense, if in the reasonable judgment of the Party bringing such suit, action or proceeding that the other Party is necessary for such action; provided,
however, that neither Party will be required to transfer any right, title or interest in or to any property to the other Party or any other Party to confer standing on a Party hereunder. The Party not pursuing the suit, action or proceeding
hereunder will provide reasonable assistance to the other Party, including by providing access to relevant documents and other evidence and making its employees available, subject to the other Party’s reimbursement of any reasonable out-of-pocket expenses incurred by the non-enforcing or defending Party in providing such assistance. Neither Party will settle nor
otherwise compromise any such suit, action or proceeding in a way that adversely affects the other Party’s intellectual property rights or its rights or interests with respect to the Product without such other Party’s prior written
consent. 
 (e)    Recovery. Except as otherwise agreed to by the Parties as part of a cost sharing arrangement,
any settlements, damages or other monetary awards (the “Recovery”) recovered pursuant to a suit, proceeding, or action in the Territory brought pursuant to Section 11.4(b) will be allocated first to the costs or expenses of the
Party taking such action, and second, 

  
 23 

 CONFIDENTIAL 
  

 
to the costs and expenses (if any) of the other Party (to the extent not otherwise reimbursed), and any remaining amounts will be shared by the Parties as follows: (i) if the applicable
suit, proceeding, or action was brought by DYDO, then DYDO shall retain [***] percent ([***]%) of such remaining amounts and CATALYST shall receive [***] percent ([***]%); (ii) if the applicable suit, proceeding, or action was brought by CATALYST,
then CATALYST shall retain [***] percent ([***]%) of such remaining amounts and DYDO shall receive [***] percent ([***]%); and (iii) if the applicable suit, proceeding or action was brought by Licensor, then Licensor shall retain [***] percent
([***]%) and DYDO shall retain [***] percent ([***]%). CATALYST shall have the sole right to any and all Recoveries obtained pursuant to a suit, proceeding, or action relating to an enforcement brought pursuant to
Section 11.4(c).     
 ARTICLE 12. 

REPRESENTATIONS AND WARRANTIES 

12.1    Mutual Representations and Warranties. Each Party represents and warrants to the other Party as follows,
which representations and warranties shall be true as at the date hereof and throughout the term of this Agreement: 

(a)    it has full corporate power and authority and has taken all corporate action necessary to enter and perform its
obligations under this Agreement; 
 (b)    this Agreement is its legal, valid, and binding obligation, enforceable in
accordance with the terms and conditions hereof; and 
 (c)    it has not violated and will not violate any provision of
the U.S. Foreign Corrupt Practices Act of 1977, the OECD Convention on Bribery of Foreign Public Officials in International Business Transactions, and the rules and regulations thereunder and any other similar foreign or domestic law or regulation;
or made or make any bribe, rebate, payoff, influence payment, kickback or other unlawful payment in connection with this Agreement and it has policies and procedures to ensure, and which are reasonably expected to ensure, continued compliance with
the provisions of this paragraph. 
 12.2    CATALYST General Warranties. CATALYST represents and warrants to
DYDO as follows: 
 (a)    Agreement Will Not Cause Breach. The execution, delivery and performance of this
Agreement by CATALYST will not result in CATALYST’s violation of or default under any Applicable Laws or any material agreement or instrument by which CATALYST is bound; 

(b)    No Lawsuits. To the best of its knowledge, and as of the date hereof, there have not been any claims,
lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, or complaints or investigations by any Third Party or government authority threatened, commenced, pending or proceeding against CATALYST, and CATALYST has not
received any notice thereof, which relate to the Product, the API, or CATALYST’s right to develop, manufacture, use or sell the Product and/or the API, or which could materially prevent CATALYST from complying with its obligations under this
Agreement; and 

  
 24 

 CONFIDENTIAL 
  

 (c)    License. CATALYST to its knowledge has the right to grant
DYDO all the licenses to DYDO set forth in this Agreement. 
 12.3    DYDO General Warranties. DYDO represents
and warrants to CATALYST that: 
 (a)    Agreement Will Not Cause Breach. The execution, delivery, and
performance of this Agreement by DYDO will not result in DYDO’s violation of or default under any Applicable Laws or any material agreement or instrument by which DYDO is bound; and 

(b)    No Lawsuits. To the best of its knowledge, and as of the date hereof, there have not been any claims,
lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, or complaints or investigations by any Third Party or government authority threatened, commenced, pending or proceeding against DYDO, and DYDO has not received any
notice thereof, which could prevent DYDO from complying with its material obligations under this Agreement. 

12.4    Disclaimer. EXCEPT FOR THE WARRANTIES AND REPRESENTATIONS PROVIDED OR REFERENCED IN THIS AGREEMENT, THE
PARTIES MAKE NO OTHER WARRANTIES OR REPRESENTATIONS TO EACH OTHER, EXPRESS OR IMPLIED, INCLUDING THOSE WITH RESPECT TO THE PRODUCT, WHETHER STATUTORY OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES, INCLUDING ANY IMPLIED
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 ARTICLE 13. 

COVENANTS OF CATALYST 

13.1    Compliance. CATALYST shall comply and will exercise its Commercially Reasonable Efforts to cause its
Contract Manufacturer to comply with all applicable GMPs, GLPs, Applicable Laws, and all applicable licenses, governmental permits or applications. 

13.2    Permits and Licenses. Subject to the other terms and conditions of this Agreement, CATALYST or its Contract
Manufacturer shall throughout the term of this Agreement, at its expense, obtain and maintain any and all licenses, permits, orders, authorizations and consents required to perform its obligations under this Agreement as manufacturer of the Product.

 ARTICLE 14. 

COVENANTS OF DYDO 

14.1    Compliance. DYDO shall be solely responsible for compliance with all Applicable Laws in the Territory
relating to the Marketing of the Product. Without limiting anything herein, DYDO shall comply with all Applicable Laws in performing this Agreement, including all marketing, promotional material or advertising activities conducted by it. DYDO shall
be responsible for all price reporting for the Products to all governmental agencies, as well as any Third Party pricing publications in the Territory and shall do so accurately and in a timely manner. 

  
 25 

 CONFIDENTIAL 
  

 14.2    Permits and Licenses. DYDO shall throughout the Term of
this Agreement, at its expense, obtain and maintain any and all licenses, permits, orders, authorizations and consents required by Applicable Laws to perform its obligations under this Agreement as Regulatory Approval holder and as importer and
distributor of the Product. 
 ARTICLE 15. 

TERM AND TERMINATION 

15.1    Term. This Agreement shall commence upon the Effective Date, and, unless terminated earlier in accordance
with the provisions hereof, shall continue for so long as the Product maintains exclusivity against competition by a generic version of the Product marketed for the same indication as the Product (the “Initial Term”). The Parties
may, in the exercise of their respective discretion mutually agree to renew the Term of this Agreement for subsequent terms of one year each (each “Renewal Term”; the Initial Term and each Renewal Term shall be collectively referred
to as the “Term”) with the same terms and conditions as previously in effect. 

15.2    Termination. If any one or more of the following events occur, then this Agreement may be terminated as set
forth herein: 
 (a)    if, at any time following the third anniversary of the Launch Date, DYDO elects to terminate the
Agreement in its discretion, without cause, then DYDO shall provide CATALYST with twelve months prior written notice and this Agreement will terminate on the first anniversary date of such written notice; 

(b)    if a Party files a petition in bankruptcy or is adjudged as bankrupt, or a petition in bankruptcy is filed against
it and is not dismissed within sixty (60) days, or it becomes insolvent, takes advantage of legislation for creditor relief, has a receiver or receiver-manager appointed in relation to its assets, or discontinues its business, then the other
Party may terminate this Agreement immediately upon delivering written notice of termination; 
 (c)    if a Party
materially breaches any of its undertakings, agreements, covenants or obligations under this Agreement (excluding matters otherwise specifically addressed with a termination right elsewhere in this Agreement) and the failure is not capable of cure
or, if capable of cure, is not remedied within sixty (60) days (or five (5) Business Days in the event of a payment default) after receipt of written notice from the non-defaulting Party, then the
non-defaulting Party may terminate this Agreement immediately upon delivering written notice of termination; 

(d)    if a Party willfully or fraudulently misrepresents any fact, information or report required to be made or disclosed
under this Agreement, then the other Party may terminate this Agreement immediately upon delivering written notice of termination; 

(e)    if the rights of CATALYST to the Licensed Technology in the Territory are terminated under the CATALYST License,
this Agreement shall automatically terminate; and 
 (f)    if a Party elects to terminate this Agreement in accordance
with a right granted to such Party under another provision of this Agreement including Sections 4.4(c), 11.3 or 18.5 or Schedule A. 

  
 26 

 CONFIDENTIAL 
  

 15.3    Expiration; Termination. 

(a)    Effect on Confidential Information and Regulatory Approval. If this Agreement expires or is terminated for
any reason, (i) the unperformed obligations of each Party shall remain in effect except that, in the event of the termination of this Agreement by CATALYST under Sections 15.2(b), (c) or (d) or Section 11.3(3), CATALYST may, but shall
not be required to, fulfill any outstanding unfulfilled purchase orders; (ii) the applicable provisions of Article 16 of this Agreement with respect to indemnity and other matters shall remain in full force and effect; and (iii) DYDO will
immediately transfer without charge (except as provided in Section 15.3(c)) all Regulatory Approvals and all related assets of DYDO related exclusively to the Product (such as customer lists related to sales of the Product) to CATALYST or its
designee, shall deliver all such tangible assets to CATALYST or its designees, and shall cooperate with CATALYST or its designee to ensure that the Regulatory Approvals may be validly owned and exercised by CATALYST or its designee; provided, that,
upon completion of the transfer of any inventory of the Product from DYDO to CATALYST, CATALYST shall reimburse DYDO for the Transfer Price paid by DYDO to CATALYST for any unexpired inventory so transferred and third party out of pocket shipping
costs to transfer such inventory. Each Party shall destroy all of the other Party’s Confidential Information in its possession (whatever the format, except that information in archival electronic records maintained in the normal course of
business need not be destroyed) except for documents that must be retained in order to comply with Applicable Laws, which information may be retained, but only for so long as required and subject to the confidentiality obligations herein. 

(b)    Wind-up Activities. Upon expiration or termination of this Agreement
for any reason: 
 (i) The Parties shall proceed, as expeditiously as possible, to wind-up all of
DYDO’s or its Affiliates’ Development and Marketing of Product then on-going in the Territory and transition of such Development and Marketing to CATALYST or its designee(s), in accordance with all
Applicable Laws and such procedures as the Parties may mutually agree to adopt. In the event that DYDO or its Affiliates is then performing any Development activities, the Parties shall promptly work together in good faith to adopt a plan to
wind-down such Development activities in an orderly fashion or, at CATALYST’s election, promptly transition such Development activities to CATALYST or its designee(s), in either case with due regard for patient safety and the rights of any
subjects that are participants in any clinical trials, and take any actions deemed reasonably necessary or appropriate to avoid any human health or safety problems and to be in compliance with all Applicable Laws. 

(ii) All licenses granted by CATALYST to DYDO under this Agreement shall terminate, and all rights under the Licensed Technology shall revert
to CATALYST; provided, however that the licenses granted to DYDO shall continue in effect on a non-exclusive basis during wind-up and transition of Development
and DYDO Marketing to CATALYST or its designee(s) and shall be limited to such wind-up and transition activities. 

(iii) DYDO and its Affiliates shall discontinue making any representation regarding its status as a licensee of or distributor for CATALYST
for the Products. Except in connection with any wind-up or transition activities, DYDO and its Affiliates shall cease conducting any activities with respect to the Development or Marketing of any Licensed
Products unless specifically authorized to do so in writing by CATALYST after the termination and only to the extent they are authorized to do so. 

  
 27 

 CONFIDENTIAL 
  

 (iv) DYDO shall transfer and assign or cause to be transferred and assigned to CATALYST or
its designee (or to the extent not so transferable or assignable, DYDO shall take all reasonable actions to make available to CATALYST or its designee the benefits of), without charge, all Regulatory Approvals and regulatory filings, and other
similar regulatory applications, permits or licenses owned or filed by DYDO or its Affiliates, and all other assets of DYDO or its Affiliates related exclusively to the Product. DYDO shall also take such actions and execute such other instruments,
assignments and documents as may be necessary to effect the transfer of rights thereunder to CATALYST or its designee and shall provide full copies of all such Regulatory Approvals and regulatory filings that are in DYDO’s possession without
charge. 
 (v) DYDO will provide to CATALYST without charge copies of all material reports and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of DYDO or its Affiliates pursuant to this Agreement that relate to the Product, within sixty (60) days of such expiration or termination,
except where CATALYST has already provided such report or data under Article 4. 
 (vi) At CATALYST’s request, DYDO shall promptly
provide to CATALYST without charge copies of all clinical trial, contract manufacturing, or service agreements entered into by DYDO or its Affiliates with respect to the Product. At CATALYST’s request, DYDO shall promptly assign (or cause to be
assigned), such agreements to CATALYST or its designee without charge. 
 (c)    In the event of a termination of this
Agreement by CATALYST pursuant to the terms contained in Schedule A, then CATALYST shall reimburse DYDO for any reasonable, necessary and documented third party out of pocket costs (not including legal fees or expenses) incurred by DYDO to
effectuate the transfers to CATALYST or its designee required by this section. 
 15.4    Termination under
Section 15.2(e). In the event of the termination of this Agreement under Section 15.2(e) after obtaining Regulatory Approval and payment of the applicable Milestone Payments, CATALYST agrees to [***] 

  
 28 

 CONFIDENTIAL 
  

 15.5    Termination Not Exclusive Remedy. Except as may otherwise
be expressly provided for herein, termination of this Agreement due to a Party’s breach shall be without limitation to any other remedy a non-defaulting Party may have because of the breach. 

ARTICLE 16. 

INDEMNIFICATION AND INSURANCE 

16.1    Indemnification of CATALYST. DYDO shall defend, indemnify, and hold harmless CATALYST, its Affiliates and
their respective officers, directors, employees, agents and representatives from and against all Losses arising in connection with any Third Party claim, action, cause of action or demand resulting from: 

(a)    any breach of this Agreement by DYDO; 

(b)    any negligent or intentionally wrongful act or omission of DYDO or any person acting on DYDO’s behalf; 

(c)    DYDO’s specific written instructions to CATALYST regarding the Product Packaging; and 

(d)    the transportation, storage (after shipment to DYDO), or Marketing of the Product. 

16.2    Indemnification of DYDO. CATALYST shall defend, indemnify, and hold harmless DYDO, its Affiliates and their
respective officers, directors, employees, agents and representatives from and against all Losses arising in connection with any Third Party claim, action, cause of action or demand resulting from: 

(a)    any breach of this Agreement by CATALYST; 

(b)    the negligent or intentionally wrongful act or omission of CATALYST or any person acting on CATALYST’s behalf;
and 
 (c)    the manufacture of any Product that is Defective; 

16.3    Indemnification Procedure. If either Party (the “Indemnified Party”) becomes aware of any
event, circumstance, assertion, demand, suit, action, claim or proceeding in respect of which the other Party (the “Indemnifying Party”) is obliged to indemnify the Indemnified Party pursuant to this Agreement, then the Indemnified
Party shall promptly give written notice thereof to the Indemnifying Party. The notice shall specify the nature and amount of the Third Party claim, to the extent that such information is available. The Indemnifying Party shall, at its expense,
assume control of the negotiation, settlement, defense or other handling of the Third Party claim for and on behalf of the Indemnified Party. The Indemnifying Party shall have the sole right to select and direct legal counsel to defend the claim.
The Indemnified Party may, at its own expense, appoint its own legal counsel to participate in defending the claim, in which case the Indemnifying Party’s counsel will consult with the Indemnified Party’s counsel and will give the
Indemnified Party’s counsel the opportunity to provide comments on the defense strategy. The Indemnified Party shall cooperate with the Indemnifying Party, including assisting in the location 

  
 29 

 CONFIDENTIAL 
  

 
and production of evidence and having its employees and other representatives testify in any court proceeding, if necessary, all at the Indemnifying Party’s reasonable cost. If the
Indemnifying Party assumes control of the claim, the Indemnified Party shall not settle or compromise the claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, and in any event an Indemnifying
Party may settle without the consent of the Indemnified Party if there is no admission of fault by the Indemnified Party and the Indemnified Party has no further obligations in respect of the claims. The Indemnifying Party shall not settle the claim
or consent to judgment without the Indemnified Party’s written approval, which approval shall not to be unreasonably withheld. If the Indemnifying Party fails to assume control of the defense of any Third Party claim, or, having elected to
assume control, thereafter fails to diligently defend the claim, then the Indemnified Party shall be entitled to contest, settle or pay the amount of the claim in good faith, and the Indemnifying Party shall be bound by the results obtained by the
Indemnified Party with respect to the claim and shall remain liable to indemnify the Indemnified Party in relation thereto. 

16.4    Insurance. CATALYST and DYDO shall, during the Term of this Agreement and for a period of five
(5) years after the expiration date of the last unit of Product sold in the Territory, maintain a policy of general commercial liability, of clinical trial liability insurance and of product liability insurance for the Product insuring against,
among other things, personal injury, death and damage to property. The said policy shall have a general commercial liability (including product liability) limit of not less than [***] Japanese Yen (JPY[***]) per occurrence and [***] Japanese Yen
(JPY[***]) in the aggregate and a clinical trial limit of not less than [***] Japanese Yen (JPY[***]) per occurrence and [***] Japanese Yen (JPY[***]) in the aggregate and shall be maintained with a financially sound and reputable insurer. 

16.5    Survival. The expiration or earlier termination of this Agreement shall not relieve any Party hereto from
any obligations which accrued prior to such expiration or earlier termination, and shall not destroy or diminish the binding force and effect of any of the terms and conditions of this Agreement that expressly or by implication come into or continue
in effect on or after termination or expiration. Without limiting the foregoing, the obligations set forth in this Article 16, Article 17 and Section 8.4 shall survive the termination of this Agreement and remain in full force and effect
for an indefinite period after termination 
 16.6    LIMITATION OF LIABILITY. 

(a)    NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER
FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES OR EXPENSES (INCLUDING LOST USE, LOST PROFITS AND LOSS OF BUSINESS), WHETHER IN CONTRACT, TORT OR OTHERWISE IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, EVEN IF A PARTY HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 (b)    EACH PARTY ACKNOWLEDGES THAT THE FOREGOING LIMITATIONS OF
LIABILITY REFLECT THE ALLOCATION OF RISK SET FORTH IN THIS AGREEMENT AND THAT NEITHER PARTY WOULD ENTER INTO THIS AGREEMENT ABSENT THESE LIMITATIONS OF LIABILITY. 

  
 30 

 CONFIDENTIAL 
  

 ARTICLE 17. 

CONFIDENTIALITY 

17.1    Confidentiality. During the term of this Agreement and for five (5) years thereafter, each Party shall
maintain in strict confidence the Confidential Information (as defined below) of the other Party. A Party may not use the Confidential Information of the other Party for any purpose other than the purposes contemplated under this Agreement, and
shall not disclose such Confidential Information to any Third Party (including in connection with any publications, presentations or other disclosures) except to its (and, in the case of DYDO, its Parent’s) employees, agents, consultants or
advisors who have a need to know such Confidential Information to achieve the purposes of this Agreement, in connection with any financing or sale of business transaction, as may be required by the CATALYST License, or as otherwise contemplated
herein for the purposes of this Agreement. Each Party shall ensure that any person to whom it discloses the other Party’s Confidential Information is informed of the confidential nature of and duty not to disclose the information and is
obligated to maintain the confidentiality thereof to the same or greater extent as provided herein. Each Party may also disclose such of the Confidential Information of the other Party as may be required by Applicable Law or by any governmental
authority having jurisdiction, provided that the Party required to disclose shall, if possible, notify the other Party prior to disclosing any Confidential Information and provide such other Party with a reasonable opportunity to contest or limit
the scope of the required disclosure and assist the other Party in obtaining any protective orders as may be appropriate. 

17.2    Definition. “Confidential Information” means all proprietary technical information,
marketing, business and financial information, scientific data, information marked confidential and all other information which a reasonable person would treat confidentially that relates to the Product or the business of a Party. Confidential
Information shall not include any information which the receiving Party can show: 
 (a)    was known to or in the
possession of the receiving Party prior to its receipt from the disclosing Party; 
 (b)    is readily available to the
public other than through any act or omission of the receiving Party in contravention of this Agreement or any other agreement between the Parties; 

(c)    was disclosed by a Third Party not under an obligation of confidentiality to the disclosing Party; or 

(d)    is subsequently independently developed by the receiving Party without use of the Confidential Information as
demonstrated by written records. 
 17.3    No Publicity. Except as required by Applicable Law, neither Party
shall originate any publicity, news release or other public announcements, written or oral, whether to the public press, to stockholders, or otherwise, relating to this Agreement or any amendment hereto without the prior written approval of the
other Party, which approval shall not be unreasonably withheld. Nothing in the provision shall be deemed to prevent a Party from making such 

  
 31 

 CONFIDENTIAL 
  

 
disclosures or announcements that, in the opinion of legal counsel, are legally required of such Party; provided that in any event the non-disclosing Party
shall have the right to review any such disclosure and revise such disclosure to the extent it relates to the use of the non-disclosing Party’s Confidential Information; provided, that, (i) the
Parties may make a public announcement of the execution of this Agreement in the form of a mutually approved press release; (ii) CATALYST may report the material terms of this Agreement in its filings with US Securities and Exchange Commission
and file a copy of this Agreement as an exhibit to its filings with the SEC if, in the opinion of CATALYST’s legal counsel, such report or filing is legally required; and (iii) neither Party shall be required to seek the permission of the
other Party to repeat any information related to this Agreement that has already been publicly disclosed. 
 ARTICLE 18. 

MISCELLANEOUS 

18.1    Notice. Any notice or other document required or permitted to be given pursuant to this Agreement shall be
in writing, in English, and shall be delivered by hand or by internationally recognized overnight courier or by email, in each case addressed to the Party to whom it is to be given at the contact information shown below or at such other contact
information as the Party to whom such notice is to be given shall have last notified the other Party in accordance with the provisions of this section: 

In the case of CATALYST at: 

Catalyst Pharmaceuticals, Inc. 

355 Alhambra Circle, Suite 801 

Coral Gables, FL 33134 

Attention: Brian Elsbernd, Chief Legal and Compliance Officer 

Email: belsbernd@CATALYSTpharma.com 

  
 32 

 CONFIDENTIAL 
  

 And in the case of DYDO at: 

DyDo Pharma, Inc. 
 Nakanoshima
Central Tower Bldg. 18F, 2-2-7 
 Nakanoshima, Kita-ku, Osaka, 530-0005 
 Attention: Hideki Matsubara, Head of
Business Development 
 Email: hideki-matsubara@dydo.co.jp 

Any such notice or other document shall be deemed to have been given and received on the date of delivery, provided that if delivery is other than during
business hours (9:00 a.m. to 5:00 p.m., local time) on a Business Day in the place of receipt, such notice shall be deemed to have been given and received on the first Business Day thereafter. 

18.2    Relationship of the Parties. The relationship of the Parties is that of independent contractors. This
Agreement does not constitute any one Party hereto as the agent or legal representative of the other Party for any purpose whatsoever. Neither of the Parties grants to the other any right or authority to assume or create any obligation or
responsibility, express or implied, on behalf of it or in its name in any manner whatsoever, unless otherwise agreed to in writing by the other Party. 

18.3    Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their
respective successors and permitted assigns. Except as otherwise expressly provided herein, DYDO may not assign or transfer it rights or obligations under this Agreement, in whole or in part, or effect a change of control, without the prior written
consent of the other Party, which consent shall not be unreasonably withheld or delayed. Any assignment or transfer by DYDO other than in accordance with the terms hereof shall be void and shall entitle the CATALYST to terminate this Agreement.
CATALYST may assign or transfer its rights and obligations hereunder or effect a change of control. 
 18.4    No
Waiver; Remedies. No Party to this Agreement shall be deemed or taken to have waived any provision of this Agreement unless such waiver is in writing, and then such waiver shall be limited to the circumstances set forth in such written waiver.
No failure or delay on the part of a Party in exercising any right, power or remedy shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the
exercise of any other right, power or remedy. All remedies provided for hereunder shall be cumulative of and in addition to any and all other remedies which any Party may have under this Agreement and/or under Applicable Law, and the exercise of any
one or more of such remedies shall not preclude the exercise of any others. The prevailing Party in any litigation hereunder shall be entitled to recovery of its attorney’s fees from the non-prevailing
Party. 
 18.5    Time. Time shall be of the essence of this Agreement and every part hereof. 

18.6    Force Majeure. If either Party is prevented from complying, either totally or in part, with any of the
terms or provisions of this Agreement by reason of force majeure, including fire, flood, earthquake, storm, general strike, lockout, riot, war, terrorism, rebellion, accident, infestation, epidemic/pandemic, governmental action, acts of God and/or
any other cause or 

  
 33 

 CONFIDENTIAL 
  

 
externally induced casualty beyond its reasonable control, whether similar to the foregoing matters or not (a “Force Majeure Event”), then, upon written notice by the Party
liable to perform to the other Party, the requirements of this Agreement or such of its provisions as may be affected, and to the extent so affected, shall be suspended during the period of such disability, provided that the Party asserting force
majeure shall bear the burden of establishing the existence of such Force Majeure Event by clear and convincing evidence, and provided further that the Party prevented from complying shall use its Commercially Reasonable Efforts to remove such
disability, and shall continue performance with the utmost dispatch whenever such causes are removed, and shall notify the other Party of the Force Majeure Event not more than five (5) Business Days from the time of the event. When such
circumstances arise, the Parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an equitable solution. If a Force Majeure Event continues for a period of longer than six
(6) consecutive months or one hundred eighty (180) days in any twelve (12) month period, then the Party unaffected by such event may terminate this Agreement upon giving not less than thirty (30) days written notice of
termination to the other Party, provided that if the Force Majeure Event ceases within such thirty (30) day period this Agreement shall remain in full force and effect. 

18.7    Governing Law and Dispute Resolution. 

(a)    This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 

(b)    Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be determined by
arbitration administered by the International Centre for Dispute Resolution in accordance with its International Arbitration Rules. The Parties and Parent expressly contemplate and agree that Parent may be joined as an additional party and shall be
subject to the jurisdiction of the arbitration tribunal. All disputes shall be heard by a single arbitrator, unless the claim amount exceeds [***] USD or the claim involves the enforcement (including by specific performance) of section 15.3, in
which case the dispute shall be heard by a panel of three arbitrators. The place of arbitration shall be Wilmington, Delaware, United States. The language of the arbitration shall be English. Within 20 days after the commencement of
arbitration, each Party shall select a person to serve as an arbitrator. The two selected arbitrators shall then select the presiding arbitrator within 30 days after completion of the appointment of the Party selections. If any arbitrators are not
selected within these time periods, the International Centre for Dispute Resolution shall, at the written request of any Party, complete the appointments that have not been made. The arbitrator, or arbitration tribunal if applicable, shall follow
IBA’s Rules on the Taking of Evidence in International Arbitration, as amended. Except as may be required by law, neither a Party nor its representatives may disclose the existence,
content, or results of any arbitration hereunder without the prior written consent of all Parties. Such award of the arbitrator, or arbitration tribunal if applicable, shall be the final award. 

18.8    CATALYST License. DYDO acknowledges that CATALYST’s rights to the Licensed Technology arise under the
CATALYST License. Notwithstanding any provision of this Agreement to the contrary, CATALYST and DYDO hereby expressly agree that: (i) it is the intent of the Parties that the terms of this Agreement and the terms of the CATALYST License be read
in concert with one another such that the terms do not conflict; (ii) in the event of any conflict between this Agreement and the CATALYST License, as between CATALYST and DYDO the terms, 

  
 34 

 CONFIDENTIAL 
  

 
covenants, conditions, and limitations of this Agreement shall control; and (iii) each Party shall not do or fail to do or permit to be done anything under this Agreement which would result
in a breach or default under any term, covenant, or condition of the CATALYST License. 
 18.9    Severability.
If any provision in this Agreement is held to be invalid, void or unenforceable, then that provision shall be severed from this Agreement, and the remainder of this Agreement shall not be affected thereby and shall be enforced to the fullest extent
permitted by Applicable Law. The Parties agree to renegotiate any such invalid, void or unenforceable provision in good faith in order to provide a reasonably acceptable alternative consistent with the basic purposes of this Agreement and to as
closely as possible give effect to the intent of the invalid, void or unenforceable provision. 
 18.10    Entire
Agreement. This Agreement (including the Schedules attached hereto and any Quality Agreement and any Pharmacovigilance Agreement entered into by the Parties) constitutes the entire agreement between the Parties with respect to the subject matter
hereof, and all prior or agreements, whether written or oral, are superseded hereby. This Agreement may be amended only in writing executed by the Parties. 

18.11    Headings. The captions and headings contained herein are for convenience of the Parties and in no way
define, limit, or describe the scope of this Agreement. 
 18.12    Language. The language of this Agreement and
all proceedings, reports, plans, related agreements or other communications between the Parties undertaken in relation thereto shall be English unless otherwise set forth herein. 

18.13    Currency. Unless otherwise specifically provided, all references to money amounts are expressed in terms
of United States dollars and all payments shall be made in US Dollars. Milestone Payments and the Transfer Price shall be converted from JPY to US Dollars using the exchange rate as published by the Wall Street Journal (U.S., Western Edition,
https://www.wsj.com/market-data/currencies) on the invoice date of which the applicable payment. Net Sales shall be reported in Japanese Yen and CATALYST shall use the same published exchange rate in effect for the last Business Day of the
applicable Quarter for which Net Sales is being reported. 
 18.14    Counterparts and Delivery. This Agreement
may be executed in any number of counterparts, each of which shall be deemed an original and all of which, taken together, shall constitute one and the same instrument. This Agreement may be executed and delivered by pdf or other form of electronic
transmission, and the Parties may rely on a pdf or electronic signature as though it were an original signature. 

18.15    Parent Guaranty. DyDo Group Holdings, Inc., a corporation incorporated under the laws of Japan
(“Parent”), has entered into this Agreement to unconditionally guaranty the payment and performance by DYDO of each and all of DYDO’s obligations under this Agreement and Parent agrees to be liable under this guaranty without
the necessity for any prior demand or notice by CATALYST to DYDO or Parent. 

  
 35 

 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the Parties and Parent hereto have executed this Agreement as of the Effective
Date. 
  

									
	DyDo Pharma, Inc.	  		  	Catalyst Pharmaceuticals, Inc.
					
	By:	 	 /s/ Yasunori Inaoka
	  		  	By:	 	 /s/ Patrick J. McEnamy

	Name: Yasunori Inaoka	  		  	Name: Pat McEnany
	Title: President and Representative Director	  		  	Title: President and CEO

 DyDo Group Holdings, Inc. 
  

			
	By:	 	 /s/ Tomiya Takamatsu

	Name: Tomiya Takamatsu
	Title: President

  
 36 

 CONFIDENTIAL 
  

 SCHEDULE A 

PRODUCT INFORMATION 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]